Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions

Ezequiel Ridruejo, Matías Javier Pereson, Diego M Flichman, Federico Alejandro Di Lello

ORCID number: Ezequiel Ridruejo 0000-0002-3321-0683; Matías Javier Pereson 0000-0002-7842-8838; Diego M Flichman 0000-0001-5730-154X; Federico Alejandro Di Lello 0000-0001-9771-9785.

Author contributions: Ridruejo E and Di Lello FA designed and wrote the manuscript; Pereson MJ and Flichman DM wrote the manuscript.

Conflict-of-interest statement: The authors declare that they have no conflicting interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Abstract

The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has shown a high rate (> 95%) of sustained virological response even when high baseline RAS prevalence has been reported. In the context of RAS emergence and high rates of sustained viral response, the clinical relevance of variants harboring RAS is still controversial. Therefore, in order to summarize the data available in international guidelines, we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.

Key Words: Hepatitis C virus; Treatment failure; Resistance; Direct-acting antiviral

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The presence of resistance-associated substitutions (RAS) to hepatitis C virus (HCV) treatment is a frequent event. Direct-acting antiviral (DAA) treatment repre-
Testing resistance for HCV

INTRODUCTION

For years, the only available treatment for chronic hepatitis C virus (HCV) infection was pegylated interferon and its combination with ribavirin (PEG-IFN/RBV) therapy. However, the sustained viral response (SVR) to treatment of infected patients was limited, varying between 42% and 46% for HCV genotype 1, about 60% for HCV genotype 4, and 76% to 80% for HCV genotype 2 or 3[1-5]. The outcomes were troublesome in patients coinfected with human immunodeficiency virus/HCV, whose SVR rates were even lower[6-9]. Fortunately, treatment against HCV infection has improved significantly in the last decade, changing from a nonspecific immunomodulatory therapy with multiple and severe side effects, such as PEG-IFN/RBV, to specific viral target options such as direct-acting antiviral (DAA) drugs against NS3, NS5A, and NS5B proteins. Thus, since the development of the latest generation of DAA drugs, the SVR is achieved in 95% to 99% of treated patients[10]. Although this scenario is very encouraging, the 1% to 5% of patients who do not achieve SVR are the pitfall of DAA therapy. Therefore, the current complex challenge is to rescue patients who fail to one or more DAA schemes.

Response to treatment with PEG-IFN/RBV was associated with viral variants and single nucleotide polymorphisms[11-17]. The introduction of DAA drugs implied a higher specific and targeted pressure on the virus, which favor the selection of resistance-associated substitutions (RAS) to different antiviral agents. In this context, virological failure was associated with RAS that may be present either from the beginning (baseline RAS) of treatment or acquired during it[18].

Naturally, HCV produces approximately $10^8$ viral particles per day[19]. In addition, the viral replication complex lacks proofreading activity, resulting in a large amount of viral variants in each infected individual. Although, in theory, all possible mutants can be produced in just 1 day, not all of them are able to remain in the population. That is because some viral genome regions have constraints and most mutations generate variants that impair viral fitness and, therefore, do not proliferate. As a result, a large mutant spectrum known as quasispecies is generated[20]. The quasispecies, that represent the lowest level of viral diversity, drives virus adaptability and constitute the greatest challenge to treatment resistance[20].

DAA drug administration inhibits wild-type HCV variants allowing the selection of reduced susceptibility variants, which present a better fitness to this environment. Although initially they do so inefficiently, over time they develop compensatory amino acid substitutions that have a higher fitness and increase the frequency of resistant variants in the quasispecies spectrum (Figure 1). Additionally, each antiviral drug has a different genetic barrier that is characterized by a threshold above which DAA resistance develops. The threshold is determined by several factors including the number of required nucleotide mutations, the level of resistance, and the viral variant fitness. Therefore, even when a viral variant with a RAS emerges, it does not mean that it is sufficient to lead to therapeutic failure. In that way, therapeutic outcome will depend on a finely poised and complex balance between the DAA genetic barrier and viral-resistant variant fitness. Consequently, a highly resistant strain with a low replication capacity will be clinically less relevant than a less resistant one that replicates more efficiently. Fortunately, more powerful DAA drugs with greater genetic barriers have been developed in the last few years[21].

In preclinical and in real-life studies, the reported prevalence rate of baseline RAS is around 5% to 40%, raising concern of the effect on reducing SVR[22-28]. Eventually, the adverse impact of baseline RAS could be minimized by extending treatment...
Figure 1 Quasispecies distribution. Simplified representation of quasispecies infecting an individual. Each genome is identified with a letter. The mutation highlighted by a red triangle in the wild-type (WT) confers a selective advantage that results in dominance of that mutation after a given number of replication rounds in an untreated patient. After the pressure generated by direct-acting antiviral (DAA) treatment, a modification of the consensus sequence is observed, where a green circle confers resistance to treatment and becomes dominant. In the upper example, mutant classes are represented as circles of sizes proportional to the number of genomes in each class. Red circles represent the WT, green circles represent a variant with resistance-associated substitutions (RAS). Yellow, light blue, and purple circles are variants with changes of the WT that are not associated with treatment response.

duration or optimizing DAA regimens. However, that is not always clinically possible, as a considerable proportion of treatment failures are caused by RAS acquired during it[29,30]. Table 1 shows the most relevant RAS reported for the currently most used DAA drugs.

RAS DETERMINATION

Unfortunately, the lack of a large market of standardized commercial assays for RAS determination has led to developing in-house RAS assays, which has created a great disparity the techniques that are used, the determined RAS, and their interpretation. Two main techniques for RAS detection have been applied. One is direct sequencing (Sanger) with sensitivity that allows detecting viral species present in between 15% and 25% within quasispecies, and the second is next generation sequencing (NGS), which allows the detection of variants present in less than 1%[31,32]. NGS is thus a more sensitive technique, but it is also much more expensive. It is therefore very likely that direct sequencing will continue to be the technique of choice because of its cost/benefit in the context of the high SVR rates of currently used DAA regimens.

Since the implementation of DAA agent, the main question that has been asked is the extent to which the RAS frequency impacts the outcome of treatment. It has been reported that the presence of a low proportion of viral variants carrying RAS within the quasispecies of an infected patient would have a lesser impact on SVR rates. In fact, some studies have reported a 15% cutoff of the viral population harboring RAS from in which a drop in the virological response rate was observed. Ikeda et al[33] (2017) reported that the SVR rates to daclatasvir (DCV)/asunaprevir (ASV) in HCV-infected patients with Y93H ratios of < 1%, 1%-25%, 26%-75%, and > 76% were 99%, 100%, 71%, and 23%, respectively[33]. Similarly, using a 15% NS5A pretreatment cutoff of ledipasvir (LDV)-specific RASs, Zeuzem et al[23] (2017) reported significant differences in SVR rates in patients treated with sofosbuvir (SOF)/LDV[23]. Overall, it has been established that SVR decreases as the proportion of RAS in the quasispecies infecting a patient increases. The second question was whether there was a differential impact of RAS depending on whether the patients were treatment naïve or previously
Table 1 Hepatitis C virus resistance-associated substitutions to currently used direct-acting antiviral drugs

| Drug family                  | Drug            | Licensed for genotype | RAS                                                                 |
|------------------------------|-----------------|-----------------------|---------------------------------------------------------------------|
| NS3 inhibitors               | Glecaprevir (GLE)| 1, 2, 3, 4, 5, 6      | 36M, 56H, 156G/V, 168A/K/L/R                                         |
|                              | Grazoprevir (GZR)| 1, 4                  | 36A/L/M, 56H/F, 155G/K/L/Q/T/S, 156T/V, 168any                      |
|                              | Paritaprevir (PTV)| 1, 4                  | 36A/M, 43L, 155C/K/Q/H, 156T/V, 168any                             |
|                              | Vosilaprevir (VOX)| 1, 2, 3, 4, 5, 6      | 36A/G/L/M, 41K/R/S/V, 43L/S7V, 54S, 55A/L, 56H/F, 80K/L, 122D/G/N, 155G/K/N/K/T/W, 156L/S/T/V, 168any |
| NS5A inhibitors             | Daclatasvir (DCV)| 1, 3, 4               | 24H, 28A/M/S/T, 30D/E/G/H/K/N/Q/R/S/T, 31I/F/M/V, 32L/del, 58A/D/N/S, 62L, 93C/H/N/R/S/W |
|                              | Elbasvir (EBR)   | 1, 3, 4               | 28G/T, 30G/H/K/R/V/Y, 31F/M/V, 58D, 93C/H/N                            |
|                              | Ledipasvir (LDV) | 1, 3, 4, 5, 6         | 24N/G, 28A/M/T, 30E/G/H/K/N/R/S/T/Y, 31I/M/V, 32L/del, 38F, 58D, 92K/T, 93C/H/N/R/S/T/W |
|                              | Ombitasvir (OBV) | 1, 4                  | 28M/S/T/V, 30E/Q/R/Y, 31I/F/V, 32del, 58D, 92T, 93C/H/N/S            |
|                              | Fibrentasvir (PIB)| 1, 2, 3, 4, 5, 6      | 24R, 28G/K/S, 30K/R, 31I/M, 32del, 58C/D, 93H/N                       |
|                              | Velpatasvir (VEL)| 1, 2, 3, 4, 5, 6      | 28V, 30E/H/K, 31M/V, 32L, 93H/N/R/S/W                                 |
| NS5B nucleoside analogs     | Dasabuvir (DSV)  | 1                     | 316Y, 368T, 395G, 411S, 414T, 444K, 445F, 448C/H, 451S, 553T/V, 554S, 556G/N/R, 557R, 558R, 559G/N, 561H, 565F |
| inhibitors                  |                 |                       |                                                                     |
| NS5B non-nucleoside         | Sofosbuvir (SOF) | 1, 2, 3, 4, 5, 6      | 159F, 282R/T, 289L, 320I/V, 321A                                    |
| analogs inhibitors          |                 |                       |                                                                     |

RAS: Resistance-associated substitutions.

treated. That question will be discussed in more detail below.

**CLINICAL UTILITY OF RAS DETECTION**

The clinical impact of RAS depends particularly on both the HCV genotype/subtype and the administered DAA regimen, which varies in efficacy according to the type of RAS as well as the treatment experience and presence of cirrhosis.

**Naïve patients**

In naïve patients, the prevalence of RAS that significantly affect the response to treatment is estimated to be approximately 5%. In that case, the SVR rates of patients with RAS would be 91%, while for patients without RAS it would be approximately 99%[23,34,35]. In summary, RAS assessment prior to the beginning of treatment is not recommended for naïve patients. In previously treated patients, the situation is more complex and refers to subjects who have failed to respond to treatment with a DAA compound. In that case, the presence of post-failure RAS is more than 75%, and SVR rates are more affected. In fact, it has been reported that SVR rates are between 75% and 85% in patients with RAS, while for patients without RAS they continue to be remarkably high (> 95%)[23,34,35]. Identifying the HCV genotype/subtype before starting therapy in naïve patients, in the pangenotypic treatment era, remains useful and may be necessary when drug availability or lack of affordability require genotype-specific treatment or optimal treatment regimens. In that sense, HCV genotyping and subtyping should be performed by nucleotide sequence analysis of some coding regions, generally the core, NS3, or the NS5B coding regions, which accurately discriminates HCV subtypes[36,37]. Furthermore, the use of the NS3 or NS5B regions to determine the viral genotype and subtype also allows the detection of the baseline RAS[36]. On the other hand, as HCV subtypes, including 1b, 3b, 3g, 4r, 6u, 6v, among others, harbor a high frequency of baseline RAS, knowing the HCV subtype before treatment in regions or countries
where these subtypes are prevalent (i.e. China, South-East Asia, and sub-Saharan Africa) is strongly recommended in order to optimize treatment[38-41]. Indeed, infrequent subtypes harboring RAS that confer resistance to NS5A inhibitors should be considered for treatment with the fixed-dose combinations SOF/velpatasvir (VEL)/voxilaprevir (VOX) for 12 wk.

HCV-1 is the most prevalent genotype worldwide (46.2%), and one third of the HCV-1 that infects patients belongs to subtype 1a[42]. Several studies have reported that DAA-naïve individuals infected with HCV-1a are more difficult to treat than those infected with HCV-1b[23,43-45]. In fact, it has been observed that in the presence of cirrhosis, high baseline viral load, or failure of previous treatment with PEG-IFN/RBV, the SVR rates of patients treated with elbasvir (EBR)/grazoprevir (GZR), or SOF/LDV were significantly lower for HCV-1a compare with HCV-1b infected individuals[23,43-45]. In EBR/GZR phase III clinical studies, the SVR rate was as low as 58% in HCV-1a treatment-naive infected patients who harbored baseline NS5A RAS[46]. On the contrary, SVR rates were high (> 97%) in HCV-1b infected patients[46]. Nevertheless, the effect of RAS in HCV-1a infected patients can be overcome by extending treatment to 16 wk and adding RBV to patients with baseline NS5A RAS[44]. Therefore, NS5A resistance testing at baseline is recommended for HCV-1a infected patients with a viral load above 800,000 IU/mL if 12 wk treatment duration is intended.

In addition, pretreatment genotyping is recommended if cirrhotic patients will be treated with SOF/VEL, as baseline RAS reduce SVR rates in HCV-3 cirrhotic patients treated with that regimen. Moreover, a recent study analyzing 539 HCV-3 infected patients showed that patients with baseline Y93H and/or A30K RAS had an SVR rate of 72.2%, while HCV-3 infected patients without NS5A RAs achieved an SVR rate of 95.7% (P = 0.002)[47]. Accordingly, a large meta-analysis that included more than 6500 subjects with chronic HCV infection reported reduced effectiveness of GLE/PIB in HCV-3 infected patients with baseline RAS like A30K, Y93H, and P53del, and recommended, in order to improve prognosis of treatment outcome and selection of therapy, testing of RAS in such patients[48].

According to the American Association for the Study of the Liver Diseases guidelines, pretreatment RAS testing is recommended in cirrhotic HCV-3 infected patients because those without a baseline Y93H RAS in NS5A are eligible for 12 wk of SOF/VEL therapy. On the other hand, cirrhotic HCV-3 infected patients with baseline Y93H RAS should be treated with SOF/VEL plus RBV or SOF/VEL/VOX for 12 wk[49]. However, since HCV-3 infections are frequent in developing countries, the benefit of pretreatment screening for RAS should be weighed. On the contrary, the European Association for the Study of the Liver (EASL) guidelines recommend the same therapeutic regimen for all compensated cirrhotic patients regardless of viral genotype[50].

Retreatment for DAA failures

Even in the context of a low treatment failure rate (< 5%), the number of patients requiring retreatment is quite high because of the large number of patients with chronic HCV infection who are treated with DAA worldwide[22,24,29-30]. Currently, the main international treatment guidelines do not recommend massive testing of RAS before starting DAA treatment, although there are exceptions[49,50].

Treatment with SOF/VEL/VOX for 12 wk is one of the most promising pangenotypic regimens for rescuing patients who have failed treatment. Two phase III trials, POLARIS-1 and POLARIS-4, assessed the safety and efficacy of the SOF/VEL/VOX regimen for 12 wk in patients who failed treatment with NS3 and/or NS5A inhibitors[51]. In the POLARIS-1 study, which included 263 patients with NS5A inhibitor failure, the overall retreatment SVR rate was 96% (one breakthrough and six relapses). As expected, cirrhotic patients, who constituted 46% of the study population, had lower SVR than noncirrhotic patients (93% vs 99%, respectively). It is important to highlight that neither the HCV genotype nor the RAS profile at the beginning of retreatment influenced SVR[51,52]. Unlike POLARIS-1, the POLARIS-4 study included previously treated patients without NS5A inhibitors. Cirrhotic patients were equally represented in both studies (46%). In POLARIS-4, the overall SVR rate of retreatment with SOF/VEL/VOX for 12 wk was 98% (178/182; one relapse) compared with 90% (136/151; one breakthrough and 12 relapses) in patients retreated with SOF/VEL for 12 wk[51,52]. Regardless of patient gender, body mass index, HCV genotype, and baseline HCV-RNA levels, several real-life studies have confirmed the high SVR rates achieved with the SOF/VEL/VOX scheme in randomized clinical trials[53-56].

The other available pangenotypic option for the treatment of patients with resistant variants is GLE/PIB. However, the combination did not have a suitable genetic barrier to achieve optimal SVR rates in patients failing previous DAA treatment[57]. In the
MAGELLAN-1 Part 2 study, GLE/PIB was used for the retreatment of previous DAA failures. SVR12 was achieved by 89% and 91% of HCV-1 and HCV-4 infected patients who received 12 wk and 16 wk of treatment, respectively. Previous treatment with one inhibitor class (protease or NS5A) had no impact on SVR12, whereas past treatment with both classes of inhibitors was associated with lower SVR12 rates\[57\]. Another study adds support of the efficacy of the 16 wk regimen for retreatment of HCV-1 infected patients with a history of sofosbuvir/NS5A inhibitor treatment failure\[38\]. Consequently, treatment with GLE/PIB is recommended as an alternative regimen for the retreatment of patients who failed to a prior DAA regimen including a, NS5A or NS3 inhibitor. It is not recommended for patients who have failed treatment with the combination of both inhibitors\[50\]. Therefore, at present, the SOF/VEL/VOX combination is the regimen of choice for the retreatment of patients who did not achieve SVR after a course of DAA treatment. RAS determination is not necessary before initiating treatment\[49,50\].

Currently, the most challenging scenario is represented by patients who failed combinations containing the latest generation of pangenotypic DAA agents GLE/PIB and SOF/VEL/VOX. Thus, such patients who are very difficult to cure, the combinations of SOF/VEL/VOX or SOF/GLE/PIB with RBV for 12 wk, or without RBV for 16-24 wk, are the recommended options. In a previous study, 31 patients who failed GLE/PIB were retreated with SOF/VEL/VOX achieved an SVR of 94% despite the presence of NS5A RAS in 90% of the cases\[59\]. On the other hand, in the ongoing MAGELLAN-3 study, 23 patients who failed GLE/PIB and received treatment with SOF/GLE/PIB combined with RBV achieved an SVR of 96%, despite the presence of RAS in the NS5A region in 91% of them\[60\].

Recently, failure to SOF/VEL/VOX has been reported in 40 patients\[61\]. RAS testing after SOF/VEL/VOX failure showed that all HCV-1a had either NS3 or NS5A RAS. On the contrary, in HCV-1b, individual NS3 RAS were rather rare (11%), and the overall frequency of NS5A RAS was moderate (33%). Finally, for HCV-3, RAS in NS5A (56%) and in NS3 plus NS5A (28%) were relatively frequent. In 22 of the cases, rescue treatment with SOF/GLE/PIB, with or without RBV, for 12-24 wk achieved an SVR rate of 79%. Unfortunately, as all types of DAA drugs have been used in most developing countries; failure is a real possibility. Therefore, surveillance of circulating viral variants is imperative. From a practical point of view, if DAA treatment fails, there are two possibilities: (1) To determine RAS and adjust the new DAA regime according to the result; and (2) to administer empirical DAA treatment following clinical practice guidelines.

The EASL currently recommends first line therapy regimens that do not require pretreatment RAS detection. The 2020 EASL Recommendations on Treatment of Hepatitis C state that in areas where the regimens are not available or not reimbursed, physicians who have access to reliable resistance tests can use the results to guide their decisions, according to\[50\]. Thus, the selected retreatment option depends on the availability of RAS testing, the actual access to the DAA agent indicated in the event of the failure, and the preference of the treating physician.

**CONCLUSION**

In the current clinical setting, there is no need for baseline detection of RAS before DAA therapy initiation in naive patients. The use of adequate pangenotypic regimes may overcome the effect of RAS in the first treatment. After treatment failure, RAS may be determined when available. Otherwise, SOF/VEL/VOX for 12 wk is the regimen of choice, as it has shown the highest SVR rates. GLE/PIB for 16 wk is an alternative regime and it may be used in patients who have failed NS5A or NS3 inhibitors, but not a combination of both. Failure to treatment with multiple DAA regimes may be the clearest clinical scenario for RAS detection. In such cases, rescue treatment can be guided based on the results. If after many failures, RAS detection is not available, treatment should be evaluated by multidisciplinary teams. SOF/VEL/VOX or SOF/GLE/PIB with RBV for 12 wk or without RBV for 16-24 wk are the regimens of choice as they have shown effectiveness in curing these difficult-to-treat patients.
ACKNOWLEDGEMENTS

To Silvina Heisecke, from CEMIC-CONICET, for copyediting the manuscript.

REFERENCES

1. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. *Antiviral Res* 2003; 59: 1-11 [PMID: 12834855 DOI: 10.1016/s0166-3542(03)00088-3]

2. Feld JJ. Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* 2005; 436: 967-972 [PMID: 16107837 DOI: 10.1038/nature04082]

3. Manns MP, Hutchinson. GD, Scully SC, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)60102-5]

4. Sánchez-Tapia JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solà R, García-Bengoechea M, García-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R, TeraVIC-4 Study Group. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. *Gastroenterology* 2006; 131: 451-460 [PMID: 16890599 DOI: 10.1053/j.gastro.2006.05.016]

5. Mira JA, Rivero A, de Los Santos-Gil L, López-Cortés LF, Girón-González JA, Márquez M, Merino D, del Mar Vitoria M, Téllez F, Rios-Villegas MJ, Omar M, Rivero-Juárez A, Macías J, Pineda JA; Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. *AIDS* 2012; 26: 1721-1724 [PMID: 22695304 DOI: 10.1097/QAD.0b013e3283568884]

6. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lune-L-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Pirho L, Salomon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. *JAMA* 2004; 292: 2839-2848 [PMID: 15598915 DOI: 10.1001/jama.292.23.2839]

7. Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebeigóo K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Cheverret S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martín-Carbonero L, García-Samaniego J, Nuñez M, PRESCO Study Group. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. *Antivir Ther* 2007; 12: 469-476 [PMID: 17668555]

8. Vispo E, Barreiro P, Pineda JA, Mira JA, Maia I, Martín-Carbonero L, Rodríguez-Novoña S, Santos I, López-Cortés LF, Merino D, Rivero A, Soriano V. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. *Antivir Ther* 2008; 13: 429-437 [PMID: 18572756]

9. Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Rios-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. *J Antimicrob Chemother* 2008; 62: 1365-1373 [PMID: 18854330 DOI: 10.1093/jac/dkn420]

10. Holmes JA, Rutledge SM, Chung RT. Direct-acting antiviral treatment for hepatitis C. *Lancet* 2019; 393: 1392-1394 [PMID: 30761525 DOI: 10.1016/S0140-6736(18)32326-2]

11. Enomoto N, Sakuma I, Asahina Y, Kusakari M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996; 334: 77-81 [PMID: 8531962 DOI: 10.1056/NEJM19960113113340203]

12. Pascu M, Martus P, Höhne M, Wiedemann B, Hopf U, Schreier E, Berg T. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NSSA-ISDR: a meta-analysis focused on geographical differences. *Gut* 2004; 53: 1345-1351 [PMID: 15306598 DOI: 10.1136/gut.2003.031336]

13. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takahara T, Tanaka E, Onji M, Toyota J, Ozawa Y, Iizuka Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Kabayama Y. Predictive values of amino acid sequences of the core and NSSA regions in antiviral therapy for hepatitis C: a Japanese multi-center study. *J Gastroenterol* 2009; 44: 952-963 [PMID: 19517057 DOI: 10.1007/s00535-009-0087-x]

14. Di Lello FA, Mira JA, Neukam K, Parra-Sánchez M, Guello JR, Cifuentes C, Macías J, Palomares JC, Gómez-Mateos J, Pineda JA, Real LM. Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. *Arch Virol* 2014; 159: 3343-3351 [PMID: 25161034 DOI: 10.1007/s00705-014-2209-x]

15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sullivan MR, Hutchinson S, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
16 Neumark K, Caruz A, Rivero-Juárez A, Barreiro P, Merino D, Real LM, Herrero R, Camacho A, Soriano V, Di Lelio FA, Macias J, Rivero A, Pineda JA. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. *AIDS* 2013; 27: 2715-2724 [PMID: 23842134 DOI: 10.1097/01.aids.0000432459.36970.a9]

17 Di Lelio FA, Caruz A, Rallon NI, Rivero-Juárez A, Neumak K, Barreiro P, Camacho A, Garcia-Rey S, Rivero A, Soriano V, Cifuentes C, Macias J, Pineda JA. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. *Eur J Clin Microbiol Infect Dis* 2013; 32: 1427-1435 [PMID: 23715768 DOI: 10.1007/s10096-013-1894-9]

18 Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. *Gastroenterology* 2016; 151: 70-86 [PMID: 27080301 DOI: 10.1053/j.gastro.2016.04.003]

19 Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* 1998; 282: 103-107 [PMID: 9756471 DOI: 10.1126/science.282.5386.103]

20 Domingo E, Sheldon J, Perales C. Viral quasi-species evolution. *Microbiol Mol Biol Rev* 2012; 76: 159-216 [PMID: 22688811 DOI: 10.1128/MMBR.05023-11]

21 Pearlman BL, Hinds AE. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir, glecaprevir/pibrentasvir. *Aliment Pharmacol Ther* 2018; 49: 914-923 [PMID: 30288771 DOI: 10.1111/apt.14977]

22 Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'Rear JJ, Naegel K. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. *Hepatology* 2018; 67: 2430-2448 [PMID: 29194682 DOI: 10.1002/hep.29693]

23 Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M. NSSA resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. *J Hepatol* 2017; 66: 910-918 [PMID: 28108232 DOI: 10.1016/j.jhep.2017.01.007]

24 Pérez AB, Chueca N, Macias J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MA, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selia A, Rosales JM, De la Iglesia A, Arenas JL, García-Bujalance S, Rios MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. *PloS One* 2019; 14: e0221231 [PMID: 31469856 DOI: 10.1371/journal.pone.0221231]

25 Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. *Sci Rep* 2016; 6: 20310 [PMID: 26842909 DOI: 10.1038/srep20310]

26 Martínez AP, Culasso ACA, Pérez PS, Romano V, Campos RH, Ridruejo E, Garcia G, Di Lelio FA. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K. *Virus Res* 2017; 240: 140-146 [PMID: 28837817 DOI: 10.1016/j.virusres.2017.08.006]

27 Martínez AP, García G, Ridruejo E, Culasso AC, Pérez PS, Pereson MJ, Neumak K, Flichman D, Di Lelio FA. Hepatitis C virus genotype 1 infection: Prevalence of NSSA and NSSB resistance-associated substitutions in naïve patients from Argentina. *J Med Virol* 2019; 91: 1970-1978 [PMID: 31273794 DOI: 10.1002/jmv.25556]

28 Bertoli A, Sorbo MC, Araghi M, Lenci I, Tetti E, Pollili E, Di Maio VC, Gianesseria L, Bilietti O, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxi A, Morisco F, Palitti VP, Siciliano M, Coppola N, Lapadde N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NSSA and NSSB Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. *J Hepatol* 2018; 8: 8988 [PMID: 29895871 DOI: 10.1016/s0168-8278(18)30662-y]

29 Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müller-Baust H, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüpke D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. *Gastroenterology* 2018; 154: 976-988.e4 [PMID: 29146520 DOI: 10.1053/j.gastro.2017.11.007]

30 Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shannugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. *J Hepatol* 2018; 68: 895-903 [PMID: 29221887 DOI: 10.1016/j.jhep.2017.11.032]

31 Fourthi S, Pawlotsky JM. Virologic Tools for HCV Drug Resistance Testing. *Viruses* 2015; 7: 6346-6359 [PMID: 26690198 DOI: 10.3390/v7122941]

32 Verbinnen T, Van Marck H, Vandenbroucke I, Vijgen L, Claes M, Lin TI, Simmen K, Neys J, Fanning G, Lenz O. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. *J Virol* 2010; 84: 11124-11133 [PMID: 20739521 DOI: 10.1128/JVI.01217-10]
Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H, Hiraishi T, Kobayashi M, Yasuda K, Yamamoto H, Yasuda H, Kurosaki M, Izumi N, Yotsuyanagi H, Suzuki M, Itoh F. Impact of resistance-associated variant dominance on treatment in patients with HCV genotype 1b receiving daclatasvir/asanaprevir. J Med Virol 2017; 89: 99-105 [PMID: 27329964 DOI: 10.1002/jmv.24668]

Sharafi H, Alaviani SM. Hepatitis C resistance to NSSA inhibitors: Is it going to be a problem? World Hepatol 2018; 10: 543-548 [PMID: 30310352 DOI: 10.1002/wjg.v10.8.543]

Kjellin M, Kilen H, Akaheri D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Almen S, Guteberg T, Goll R, Lanneråk T, Lennernäs J. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol 2019; 54: 1042-1050 [PMID: 31424972 DOI: 10.1080/00365521.2019.1652846]

Neukam K, Martínez AP, Caluso ACA, Ridueño E, García G, Di Lello FA. NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b. PLoS One 2017; 12: e0182193 [PMID: 28753662 DOI: 10.1371/journal.pone.0182193]

Chevaliez S, Bouvier-Alias M, Brillot R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209 [PMID: 19997618 DOI: 10.1371/journal.pone.0008209]

Childs K, Davis C, Cannon M, Montague S, Filipe A, Tong L, Simonnds P, Smith D, Thomson EC, Dusheiko G, Agarwal K. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. J Hepatol 2019; 71: 1099-1105 [PMID: 31400349 DOI: 10.1016/j.jhep.2019.07.025]

Wasitthankasem R, Vongpunsawad S, Siripon N, Suya C, Chulothoph P, Chaiar K, Rujjrojindakul P, Kanjana S, Theamboonlers A, Tangkijvanich P, Poovorawan Y. Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS One 2015; 10: e0126764 [PMID: 25962112 DOI: 10.1371/journal.pone.0126764]

Wei L, Lim SG, Xie Q, Ván KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslisuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-Sobol H, Mo H, Brandin DM, Yang YF, Dao L, Wang Q, Tanwandeep T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou J, Jia J. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol 2019; 4: 127-134 [PMID: 30555048 DOI: 10.1016/S2468-1253(18)30343-1]

Pawlotsky JM. DAA failures in African patients with "unusual” HCV subtypes: Hey! Didn’t you know there was another world? J Hepatol 2019; 71: 1070-1072 [PMID: 31648816 DOI: 10.1016/j.jhep.2019.09.021]

Messina JP, Humphreys I, Fluxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87 [PMID: 25066590 DOI: 10.1002/hep.27259]

Sarrazin C, Dvory-Sobol H, Svorvoskaia ES, Doehle BP, Pang PS, Chuang SM, Ma J, Ding X, Afshal NH, Krowdley KV, Gane EJ, Lawitz E, Brandin DM, McHutchison JG, Miller MD, Mo H. Prevalence of Resistance-Associated Substitutions in HCV NSSA, NSSB, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology 2016; 151: 501-512.e1 [PMID: 27296509 DOI: 10.1053/j.gastro.2016.06.002]

Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafraian S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lapinacci L, Barr E, Hobar B. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology 2017; 152: 164-175.e4 [PMID: 27720838 DOI: 10.1053/j.gastro.2016.09.045]

Zeuzem S, Ghalib R, Reddy KR, Pokrojs J, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med 2015; 163: 1-13 [PMID: 25909356 DOI: 10.7326/M15-0785]

Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, Strasser S, Kumada H, Wang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol 2018; 53: 679-688 [PMID: 29344726 DOI: 10.1002/jgino.20183-1429-3]

Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morisca G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pascazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxi A, Andreoni M, Ceccherini-Silberstein F, HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. Liver Int 2021; 41: 1802-1814 [PMID: 33497016 DOI: 10.1111/liv.14797]

Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021; 28: 177-185 [PMID: 32961624 DOI: 10.1111/jvh.13409]
Ridruejo E et al. Testing resistance for HCV

49 Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. 
*Hepatology* 2020; 71: 686-721 [PMID: 31816111 DOI: 10.1002/hep.31060]

50 European Association for the Study of the Liver: Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series. *J Hepatol* 2020; 73: 1170-1218 [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.015]

51 Bouriére M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stammi LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schift ER, Reddy KR, Manns MP, Kowdlely KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. *N Engl J Med* 2017; 376: 2134-2146 [PMID: 28564569 DOI: 10.1056/NEJMoa1613512]

52 Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdlely KV, Roberts SK, Dvory-Sobol H, Svarovskaia E, Martin R, Camus G, Doehile BP, Stammi LM, Hyland RH, Brainard DM, Mo H, Gordon SC, Bouriére M, Zeuzem S, Flamm SL. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 wk in HCV DAA-experienced patients. *J Hepatol* 2018; 69: 1221-1230 [PMID: 30098573 DOI: 10.1016/j.jhep.2018.07.023]

53 Da BL, Lourdusamy V, Kusheh T, Dieterich D, Saberi B. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. *Eur J Gastroenterol Hepatol* 2021; 33: 859-861 [PMID: 32451421 DOI: 10.1097/MEG.0000000000002178]

54 Belperio PS, Shahoumian TA, Loomis TP, Backus LJ. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients. *J Viral Hepat* 2019; 26: 980-990 [PMID: 31012179 DOI: 10.1111/jvh.13115]

55 Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgiani A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zonaca A, Bonfantini P, Russo FP, Aghemo A, Centeno R, Maggiolo F, Rovida P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredi R, Carrieri C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagioli S; NAVIGATE-Lombardia and Veneto Study Groups. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. *J Hepatol* 2019; 71: 1106-1115 [PMID: 31433303 DOI: 10.1016/j.jhep.2019.07.020]

56 Llaneras J, Rivero-Barciela M, Lens S, Diago M, Cachero A, Garcia-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, Maria Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turres J, Gonzalez-Santiago JM, Montolui S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Illarramendi M, Pascaio JM, Etereban R, Maria Z, Buti M. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAAs. *J Hepatol* 2019; 71: 666-672 [PMID: 32103153 DOI: 10.1016/j.jhep.2019.06.002]

57 Poordad F, Pol S, Asattyar A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng T, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. *Hepatology* 2018; 67: 1253-1260 [PMID: 29152781 DOI: 10.1002/hep.29671]

58 Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, Hassan MA, Pearlman BL, Hinestrosa F, Jacobson IM, Morelli G, Peter JA, Vaincusirs M, Michael LC, Fried MW, Wang GP, Lu W, Larsen L, Nelson DR. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NSSA Inhibitor Plus Sofosbuvir Therapy. *Gastroenterology* 2019; 157: 1506-1517.e1 [PMID: 31401440 DOI: 10.1016/j.gastro.2019.08.008]

59 Pearlman B, Perrys M, Hinds A. Sofosbuvir/Velpatasvir/Voxilaprevir for Previously Treated Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection. *Am J Gastroenterol* 2019; 114: 1550-1552 [PMID: 31082871 DOI: 10.14309/ajg.0000000000000248]

60 Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoeher A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. *J Hepatol* 2019; 70: 1019-1023 [PMID: 30857780 DOI: 10.1016/j.jhep.2019.01.031]

61 Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paoulacci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Cecherini-Silberstein F, García F, Sarrazzin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. *J Hepatol* 2021; 74: 801-810 [PMID: 33220331 DOI: 10.1016/j.jhep.2020.11.017]
